Lyell Immunopharma, Inc. (LYEL) vs Entrada Therapeutics, Inc. (TRDA)
Lyell Immunopharma, Inc. and Entrada Therapeutics, Inc. are both Biotechnology companies. Lyell Immunopharma, Inc. and Entrada Therapeutics, Inc. are of similar size ($248.0M and $242.2M). Lyell Immunopharma, Inc. grew revenue faster over the last twelve months: −55.0% against −94.1%. Entrada Therapeutics, Inc. has the higher net margin (−3,537.7% vs −920,285.2%) and the lower return on invested capital (−1,060.2% vs −539.5%). Across the 15 metrics below, Entrada Therapeutics, Inc. leads on 10 and Lyell Immunopharma, Inc. on 5.
Valuation
Profitability
| Metric | LYEL | TRDA | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 100.00% | 65.16% |
| Operating margin | (949,981.48%) | (3,767.07%) | 0.00% |
| Net margin | (920,285.19%) | (3,537.73%) | 0.00% |
| Free cash flow margin | (647,681.48%) | (2,867.07%) | 0.00% |
| Return on equity | (93.28%) | (54.09%) | (57.72%) |
| Return on assets | (71.34%) | (44.35%) | (49.22%) |
| Return on invested capital | (539.53%) | (1,060.24%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack